Clearsight Therapeutics, Inc.
Publicly observedDallas, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Dallas | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Clearsight Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | Z3JEGN7JHR18 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2026Publicly observed
NIH SBIR/STTR award: Novel preservative-free eyedrop with antimicrobial and anti-inflammatory properties for treating Acute Infectious Conjunctivitis and Epidemic KeratoConjuntivitis (EKC)
USD 306,852.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.